Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 290 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sweat Clear all
Terminated Phase 2 Interventional Results available

Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

NCT01838499
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
MEDI8968, Saline
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
27
States / cities
Phoenix, Arizona • Bakersfield, California • Fremont, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 30, 2026, 11:38 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical and Biological Characteristics of Hidradenitis Suppurativa

NCT03967600
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Moisture Management Liner Effectiveness Study

NCT04427007
View directory record Official record
Conditions
Amputation Stumps, Amputees, Amputation, Lower Limb Deformities, Congenital, Prosthesis User, Prosthesis
Interventions
Moisture Management Liner, Control Liner
Device
Lead sponsor
Liberating Technologies, Inc.
Industry
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Holliston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 30, 2026, 11:38 AM EDT
Recruiting Phase 1 Interventional

A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS

NCT07855276
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
LOU064, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Mayfield Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Phase 3 Interventional

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

NCT00008359
View directory record Official record
Conditions
Cancer
Interventions
caspofungin acetate, liposomal amphotericin B
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Results available

Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis

NCT02129660
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Dose 1 of glycopyrrolate, 2.0% QD, Dose 2 of glycopyrrolate, 3.0% QD, Dose 1 of glycopyrronium, 2.5% QD, Dose 2 of glycopyrronium, 3.75% QD, Vehicle
Drug · Other
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Encinitas, California • Fremont, California • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 30, 2026, 11:38 AM EDT
Recruiting Early Phase 1 Interventional

Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa

NCT06058520
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Fecal Microbiota - lyophilized, Placebo drug
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 11:38 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Comparison of Hormonal Therapy: Mediating Hot Flashes Tapering Regimens for Mediating Hot Flashes

NCT00547001
View directory record Official record
Conditions
Hot Flashes, Night Sweats
Interventions
Estradiol
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
35 Years to 70 Years · Female only
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 18, 2008 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

NCT04018599
View directory record Official record
Conditions
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Interventions
40 mg MSB11022
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Not applicable Interventional

Study of Botulinum Toxin in Patients With Primary Hyperhidrosis

NCT00004480
View directory record Official record
Conditions
Hyperhidrosis
Interventions
botulinum toxin type A
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 11:38 AM EDT
Recruiting No phase listed Observational

Targeting Nociceptors in Hidradenitis Suppurativa

NCT05403710
View directory record Official record
Conditions
Hidradenitis Suppurativa, Hyperhidrosis
Interventions
Botulinum toxin
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Results available

Qbrexza Cloths for Hyperhidrosis of Amputation Sites

NCT04924036
View directory record Official record
Conditions
Amputation, Hyperhidrosis
Interventions
glycopyrronium cloths, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 30, 2026, 11:38 AM EDT
Not listed Phase 3 Interventional

Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia

NCT00020865
View directory record Official record
Conditions
Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cefepime hydrochloride, levofloxacin
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 30, 2026, 11:38 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

NCT06888193
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Santa Monica, California • South Miami, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study to Evaluate the Efficacy of Bite's Natural Deodorant

NCT05503784
View directory record Official record
Conditions
Sweat, Underarm Odor
Interventions
BITE Deodorant
Other
Lead sponsor
Kind Lab PBC.
Industry
Eligibility
24 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Oct 30, 2026, 11:38 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of Safety and Efficacy of Morpheus8 Applicator for the Treatment of Focal Hyperhidrosis of the Axillae Using Radio Frequency

NCT05860972
View directory record Official record
Conditions
Hyperhidrosis Primary Focal Axilla
Interventions
Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis.
Device
Lead sponsor
InMode MD Ltd.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
3
States / cities
New York, New York • Knoxville, Tennessee • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 30, 2026, 11:38 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

What is the Role of Type III/IV Muscle Afferents in Airway Resistance and Thermoregulatory Responses to Exercise?

NCT07452094
View directory record Official record
Conditions
Placebo - Control, Experimental
Interventions
EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Drug
Lead sponsor
Northern Arizona University
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Flagstaff, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Single-Treatment, Study of Percutaneous-Temperature Controlled-RF Electrocoagulation on Axilla Tissue

NCT03107065
View directory record Official record
Conditions
Sweating Increased Armpits
Interventions
Thermi Radiofrequency
Device
Lead sponsor
ThermiGen, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Not applicable Interventional Results available

Evaluating the Effect of a Written Action Plan on Comfort and Understanding of Hidradenitis Suppurativa

NCT04600375
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Verbal consultation, Written Action Plan
Behavioral
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 89 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT03713632
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
15
States / cities
San Diego, California • Whittier, California • Coral Gables, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

Endometrial Safety Study

NCT00522873
View directory record Official record
Conditions
Postmenopause
Interventions
0.25mg DRSP / 0.5mg E2 (BAY86-4891), 0.5mg NETA / 1.0mg E2 (Activella)
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Chandler, Arizona • San Diego, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2014 · Synced Oct 30, 2026, 11:38 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)

NCT05348681
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
RIST4721, Placebo
Drug
Lead sponsor
Aristea Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Phase 2 Interventional

An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease

NCT00071877
View directory record Official record
Conditions
Fabry Disease
Interventions
Replagal
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Not applicable Interventional

Mindfulness Training Hidradenitis Suppurativa (HS)

NCT05642039
View directory record Official record
Conditions
Hidradenitis Suppurativa, Quality of Life
Interventions
Mindfulness Course, HS Educational Course
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 30, 2026, 11:38 AM EDT